FROM CHILDHOOD TO ADULTHOOD. THE SUPORTING ROLEOF BOTULINUM TOXIN (BoNT A) INTRAMUSCULAR INJECTIONSIN SPASTICITY REGARDING THE FUNCTIONAL LEVEL EVOLUTION

Cerebral Palsy is a pediatric neurological syndrome with important outcome in children global development, with motor and postural repercussions. Near birth and birth associated medical issues are the most frequently etiological factors for cerebral palsy, with signs and symptoms that become obvious in child’s first three years of life. Thus, care providers will notice delay in age specific acquisitions (head control, sitting, standing, independent gait), high/low tone muscle, paraplegia, hemiplegia, diplegia, dyskinesia, tremor, clonu s, skeletal deformities. The most frequent deformity: pes equinus. The benefits of botulinum toxin (BoNT A) for spasticity treatment in CP children regard muscle tone attenuation; prevention of secondary contractures and decreases surgical treatment necess ity; good tolerability; can be used among other therapeutical options; individual therapeutical adaptation. In medical literature there is insufficient data for BoNT A treatment in cerebral palsy patients that are at the adult age, either if the administra tion occurred during childhood or the necessity of administration for the first time in adulthood. Objectives: continuity management for BoNT A treatment in cerebral palsy patients that have reached adulthood, observing long term outcome and the functional evolution. The scarce results mention spasticity improvement with minimal effects on gait; secondary to spasticity pain reduction.